OTCMKTS:CLVLY Clinuvel Pharmaceuticals (CLVLY) Stock Price, News & Analysis → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free CLVLY Stock Alerts $9.46 -0.29 (-2.97%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$9.46▼$9.4650-Day Range$8.54▼$10.7052-Week Range$8.54▼$13.92Volume133 shsAverage Volume4,088 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartDividendFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartDividendFinancialsHeadlinesSEC FilingsShort Interest Get Clinuvel Pharmaceuticals alerts: Email Address Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). About Clinuvel Pharmaceuticals Stock (OTCMKTS:CLVLY)Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. The company was founded in 1987 and is headquartered in Melbourne, Australia.Read More CLVLY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLVLY Stock News HeadlinesMarch 28, 2024 | globenewswire.comPhotomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German InvestorsMarch 21, 2024 | finance.yahoo.comClinuvel Pharmaceuticals (ASX:CUV) shareholders have endured a 50% loss from investing in the stock three years agoApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.March 20, 2024 | investing.comClinuvel Pharmaceuticals Ltd ADR (CLVLY)March 9, 2024 | fool.com.auThe Clinuvel Pharmaceuticals share price is up 236% in 12 monthsMarch 4, 2024 | globenewswire.comMalibu shines a light on CLINUVEL's pioneering work in photomedicineMarch 2, 2024 | wsj.comClinuvel Pharmaceuticals Ltd. ADRFebruary 25, 2024 | msn.comClinuvel Pharmaceuticals (CLVLF) Price Target Increased by 5.58% to 19.75April 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.February 23, 2024 | msn.comClinuvel Pharmaceuticals GAAP EPS of A$0.22, revenue of A$32.25BJanuary 30, 2024 | wsj.comClinuvel Pharmaceuticals Ltd.December 9, 2023 | morningstar.comClinuvel Pharmaceuticals Ltd ADRDecember 2, 2023 | morningstar.comClinuvel Pharmaceuticals Ltd ADR CLVLYOctober 31, 2023 | nasdaq.comClinuvel Pharmaceuticals Ltd - ADR (CLVLY) Price Target Increased by 18.27% to 21.08October 5, 2023 | finance.yahoo.comClinuvel Pharmaceuticals (ASX:CUV) shareholders have endured a 38% loss from investing in the stock three years agoSeptember 1, 2023 | msn.comClinuvel Pharmaceuticals (CLVLF) Price Target Increased by 12.19% to 18.70May 3, 2023 | finance.yahoo.comCould The Market Be Wrong About Clinuvel Pharmaceuticals Limited (ASX:CUV) Given Its Attractive Financial Prospects?May 1, 2023 | msn.comSome Patients With a Rare Disease Face Hurdles Getting the Only TreatmentMarch 30, 2023 | finance.yahoo.comClinuvel Pharmaceuticals (ASX:CUV) shareholders have earned a 14% CAGR over the last five yearsMarch 1, 2023 | finance.yahoo.comAnalysts Just Slashed Their Clinuvel Pharmaceuticals Limited (ASX:CUV) EPS NumbersMarch 1, 2023 | finance.yahoo.comCLINUVEL Launches CYACÊLLE, Next Generation Solar CareFebruary 25, 2023 | msn.comWhy Clinuvel, Cogstate, Omni Bridgeway, and Westgold shares are sinkingFebruary 24, 2023 | finance.yahoo.comClinuvel Pharmaceuticals First Half 2023 Earnings: EPS: AU$0.23 (vs AU$0.12 in 1H 2022)February 24, 2023 | finanznachrichten.deClinuvel Pharmaceuticals Limited: Global SCENESSE demand drives increased CLINUVEL revenues, earningsFebruary 23, 2023 | finance.yahoo.comGlobal SCENESSE® demand drives increased CLINUVEL revenues, earningsFebruary 2, 2023 | finanznachrichten.deClinuvel Pharmaceuticals Limited: CLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned IndividualsJanuary 15, 2023 | finance.yahoo.comCLINUVEL Trial Results Show Drug Reduces DNA DamageSee More Headlines Receive CLVLY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clinuvel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:CLVLY CUSIPN/A CIK1290877 Webwww.clinuvel.com Phone(139) 660-4900FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Philippe Jacques Wolgen M.B.A. (Age 61)M.D., CEO, MD & Director Comp: $1.78MMr. Darren Michael Keamy B.Com. (Age 51)CPA, CFO & Company Secretary Comp: $266.71kDr. Dennis J. WrightChief Scientific OfficerMr. Lachlan HayDirector of Global OperationsMr. Malcolm BullHead of Australian Operations & Investor RelationsDr. Rose Quadbeck-DielSenior Vice President of Regulatory AffairsDr. Azza HamilaHead of Quality & Drug SafetyMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors CLVLY Stock Analysis - Frequently Asked Questions How have CLVLY shares performed in 2024? Clinuvel Pharmaceuticals' stock was trading at $11.0550 at the start of the year. Since then, CLVLY stock has decreased by 14.4% and is now trading at $9.4640. View the best growth stocks for 2024 here. Are investors shorting Clinuvel Pharmaceuticals? Clinuvel Pharmaceuticals saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 5,500 shares, an increase of 41.0% from the March 31st total of 3,900 shares. Based on an average daily trading volume, of 6,900 shares, the days-to-cover ratio is currently 0.8 days. View Clinuvel Pharmaceuticals' Short Interest. How often does Clinuvel Pharmaceuticals pay dividends? What is the dividend yield for Clinuvel Pharmaceuticals? Clinuvel Pharmaceuticals declared a dividend on Wednesday, August 30th. Shareholders of record on Friday, September 8th will be paid a dividend of $0.0283 per share on Monday, October 2nd. The ex-dividend date of this dividend is Thursday, September 7th. This is an increase from the stock's previous dividend of $0.02. Read our dividend analysis for CLVLY. How do I buy shares of Clinuvel Pharmaceuticals? Shares of CLVLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CLVLY) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clinuvel Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
